FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at treating stage II and II non-small cell lung cancer with pre- and postoperative chemotherapy. There are involved 3 courses of the neoadjuvant chemotherapy. On the 1st and 8th days of the cycle, irinotecan 100 mg/m2 is introduced intravenously for 2 hours. On the 2nd day, 20 hours after introduction of irinotecan, carboplatin dosed AUC of 6 is introduced intravenously drop-by-drop. The time span of the chemotherapeutic course makes 25 days. That is followed by the additional postoperative adjuvant chemotherapy on the 18th day according to the above scheme in number of 2 courses.
EFFECT: improved effectiveness of the method.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF COMBINED TREATMENT OF NON-SMALL CELL LUNG CANCER OF II AND III STAGE | 2011 |
|
RU2455986C1 |
| METHOD OF COMBINED TREATMENT OF NON-SMALL CELL CANCER OF LUNG OF III STAGE | 2007 |
|
RU2340336C1 |
| METHOD OF COMBINATION TREATMENT OF NON-SMALL CELL LUNG CANCER STAGE 1B-111 WITH CUSTOMIZATION OF ADJUVANT CHEMOTHERAPY | 2015 |
|
RU2593342C1 |
| COMBINATION THERAPY OF LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER | 2007 |
|
RU2372901C2 |
| METHOD OF COMBINED TREATMENT OF LUNG CANCER STAGE III | 2007 |
|
RU2348440C2 |
| MARKING PROCEDURE FOR INTRAOPERATIVE RADIATION THERAPY TARGET WITHIN COMBINED TREATMENT OF LUNG CANCER OF TH | 2007 |
|
RU2348357C1 |
| METHOD OF COMBINATION TREATMENT OF STAGE IIIA-IIIB LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER | 2010 |
|
RU2431450C1 |
| METHOD FOR PERSONALIZED COMBINED TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER STAGE II-III | 2022 |
|
RU2784958C1 |
| METHOD FOR PREVENTION OF POSTOPERATIVE COMPLICATIONS OF COMBINED TREATMENT OF PATIENTS WITH STAGE III NON-SMALL-CELL LUNG CANCER | 2010 |
|
RU2429842C1 |
| METHOD OF PERSONALIZED COMBINED TREATMENT OF NON-CELL LUNG CANCER 1B-111 STAGE ON THE BASIS OF ESTIMATION OF THE LEVELS OF EXPRESSION OF MONORESISTENCE GENES | 2017 |
|
RU2665133C1 |
